Global Health Limited · ASX:GLH
Global Health — Investor Presentation (October 2024)
15 slides from Global Health's investor presentation, October 2024
Slide 1: Market Update
GL BAL HEALTH ‘onneci ting Clinicians and Consumers Market Update \ Ge
Slide 2: Disclaimer
Disclaimer Global Health Limited (the Company) is not offering shares. It makes no representation and gives no warranties in relation to any information it may provide. The Company disclaims all responsibility in relation to any acquisition of shares in the Company. If you wish to buy shares in the
Slide 3: Escalating and unsustainable healthcare costs
Escalating and unsustainable healthcare costs Source: AIHW.gov.au 70% of Australia’s $240B is spent on managing and supporting people living with lifelong conditions ❖ In 2021–22, Australia spent an estimated $241.3 billion on health goods and services, an average of $9,365 per person. ❖ In real ter
Slide 4: Increasing Incidence of Chronic disease
Increasing Incidence of Chronic disease Source: AIHW.gov.au 60% of Australians (15.5 million) live with 1 or more chronic disease i.e. People living with anxiety, depression, asthma, diabetes, hypertension, alcohol addiction, drug dependencies etc. In 2020–2022, an estimated 8.5 million Australians
Slide 5: Our Mission
Our Mission Enhancing health outcomes for individuals and improving operational and financial outcomes for healthcare providers with a patient-centric and connected healthcare eco-system. Global Health (ASX: GLH) develop and market a portfolio of composable software and SaaS platforms designed to di
Slide 6: Our Portfolio of SaaS Solutions
Our Portfolio of SaaS Solutions Connecting Consumers and Clinicians For Providers For Consumers Secure Connectivity Consumer Empowerment ✓ End-to-end encryption ✓ Personal health record application ✓ Shared clinical documents ✓ Empowers consumers to manage their ✓ Payload agnostic own health and sha
Slide 7: Competitive Advantage
Competitive Advantage The 5 most common chronic conditions : • anxiety (4.8 million people, 18.9%) • back problems (4.0 million people, 15.7%) • depression (3.2 million people, 12.4%) • asthma (2.8 million people, 10.8%) • deafness or hearing loss (2.4 million people, 9.6%) The 5 risk factors that c
Slide 8: Financial Performance – Expenses & EBITDA
Financial Performance – Expenses & EBITDA Over the 24 months since June 2022, Operating EBITDA improved by $2.85M from negative EBITDA of ($1.238M) before Growth R&D investments to positive EBITDA before Growth R&D investments of $1.614M in FY24. However, over the same period, investments in future
Slide 9: R&D Expenses
R&D Expenses Expenses Profile With the bulk of the Growth R&D now complete, investments in Growth R&D is forecast to reduce to $2.055M in 2025 representing 22% of total expenses. Our composable MasterCare Plus (M+) SaaS platform integrated to our HotHealth Digital Front Door and Lifecard Patient emp
Slide 10: Financial Performance - Revenue & Gross Margin
Financial Performance - Revenue & Gross Margin Revenue In the 24 months since June-22: • Customer revenue (excluding Interest income and Grants) increased by 25% • Customer Subscriptions or ARR (Annual Recurring Revenue) increased by 17%. • ARR as a percentage of Customer Revenue was 72% in the last
Slide 11: The Australian Healthcare Market Size
The Australian Healthcare Market Size HOSPITAL SPECIALISTS COMMUNITY HEALTH GENERAL ALLIED PRACTICE HEALTH CONSUMERS Patients with Chronic Disease, Corporate Employee Programs, Emerging “At-Risk” Consumers and the “Worried Well” ❖ 650 private hospitals including day hospitals ❖ 36,000 Medical Specia
Slide 12: Looking Ahead
Looking Ahead FY2025 - Revenue Target of 10% growth • Commenced rollout of our MasterCare+ SaaS platforms as an upgrade to existing Primary Care, Community Health and Hospita customers. • Commenced Value-add upsell campaigns with HotHealth Digital front Door, Microsoft Cloud Hosting and ReferralNet
Slide 13: Market Information
Market Information Additional Financial Information (as at 30 June 2024) Cash and cash equivalents $2.066,224 Borrowings (Debt) $1,026,862 Trade Receivables $849,381 Trade Payables $334,926 Intangible Assets $0 Share Information Shares on Issue 58,048.778 Unlisted options ($0.25 / 11th December 2024
Slide 14: Our Board of Directors
STEVEN STRANGE Independent Non-Executive Director Our Board of Directors Steven brings over 30 years of leadership experience to the Board at Global Health at a very opportune and pivotal time, where the Company seeks to significantly grow its business both domestically and in its positioning in the
Slide 15: Thank you for listening! For Further Information
Thank you for listening! Mathew Cherian Managing Director, Global Health Limited, For Further Information E: investor.relations@global-health.com Visit our website M: +61 409 099 788